| DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer TK Le, C Cherif, K Omabe, C Paris, F Lannes, S Audebert, E Baudelet, ... Molecular Therapy 31 (2), 471-486, 2023 | 17 | 2023 |
| Perfluorocarbon nanodroplets as potential nanocarriers for brain delivery assisted by focused ultrasound-mediated blood–brain barrier disruption C Bérard, S Desgranges, N Dumas, A Novell, B Larrat, M Hamimed, ... Pharmaceutics 14 (7), 1498, 2022 | 12 | 2022 |
| Pharmacokinetics of oral vinorelbine in French children with recurrent or progressive primary low‐grade glioma M Hamimed, F Gattacceca, N André, E Tresch‐Bruneel, A Probst, ... British Journal of Clinical Pharmacology 88 (5), 2096-2117, 2022 | 5 | 2022 |
| Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model‐based population pharmacokinetic analysis M Hamimed, P Leblond, A Dumont, F Gattacceca, E Tresch-Bruneel, ... Cancer Chemotherapy and Pharmacology 90 (1), 29-44, 2022 | 3 | 2022 |
| Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351 M Donnette, M Hamimed, J Ciccolini, Y Berda-Haddad, E Kaspi, G Venton, ... Journal of Controlled Release 338, 244-252, 2021 | 3 | 2021 |
jacques grillgustave roussy在 gustaveroussy.fr 的电子邮件经过验证
